1.83
3.39%
+0.06
Synlogic Inc stock is currently priced at $1.83, with a 24-hour trading volume of 70,286.
It has seen a +3.39% increased in the last 24 hours and a -3.68% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.77 pivot point. If it approaches the $1.86 resistance level, significant changes may occur.
Synlogic Inc Stock (SYBX) Financials Data
Synlogic Inc (SYBX) Revenue 2024
SYBX reported a revenue (TTM) of $3.37 million for the quarter ending December 31, 2023, a +185.68% rise year-over-year.
Synlogic Inc (SYBX) Net Income 2024
SYBX net income (TTM) was -$57.28 million for the quarter ending December 31, 2023, a +13.40% increase year-over-year.
Synlogic Inc (SYBX) Cash Flow 2024
SYBX recorded a free cash flow (TTM) of -$51.83 million for the quarter ending December 31, 2023, a +10.05% increase year-over-year.
Synlogic Inc (SYBX) Earnings per Share 2024
SYBX earnings per share (TTM) was -$10.75 for the quarter ending December 31, 2023, a +22.48% growth year-over-year.
Synlogic Inc Stock (SYBX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Dooley Mary Beth | Head of Finance |
Apr 02 '24 |
Sale |
1.73 |
188 |
325 |
15,231 |
Synlogic Inc Stock (SYBX) Latest News
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Synlogic Adopts Limited Duration Stockholders Rights Plan
GlobeNewswire Inc.
Crude Oil Moves Higher; Newell Brands Issues Weak Outlook
Benzinga
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Nasdaq Jumps Over 100 Points; Pinterest Sales Miss Expectations
Benzinga
About Synlogic Inc
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):